Shin Hong Kyung, Kim Jeong Hoon, Lee Do Heui, Cho Young Hyun, Kwon Do Hoon, Roh Sung Woo
Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Korean Neurosurg Soc. 2016 Jul;59(4):392-9. doi: 10.3340/jkns.2016.59.4.392. Epub 2016 Jul 8.
Brain metastases in gynecologic cancer (ovarian, endometrial, and cervical cancer) patients are rare, and the efficacy of Gamma Knife Radiosurgery (GKRS) to treat these had not been evaluated. We assessed the efficacy of GKRS and prognostic factors for tumor control and survival in brain metastasis from gynecologic cancers.
This retrospective study was approved by the institutional review board. From May 1995 to October 2012, 26 women (mean age 51.3 years, range 27-70 years) with metastatic brain tumors from gynecologic cancer were treated with GKRS. We reviewed their outcomes, radiological responses, and clinical status.
In total 24 patients (59 lesions) were available for follow-up imaging. The median follow-up time was 9 months. The mean treated tumor volume at the time of GKRS was 8185 mm(3) (range 10-19500 mm(3)), and the median dose delivered to the tumor margin was 25 Gy (range, 10-30 Gy). A local tumor control rate was 89.8% (53 of 59 tumors). The median overall survival was 9.5 months after GKRS (range, 1-102 months). Age-associated multivariate analysis indicated that the Karnofsky performance status (KPS), the recursive partitioning analysis (RPA) classification, and the number of treated lesions were significant prognostic factors for overall survival (HR=0.162, p=0.008, HR=0.107, p=0.038, and HR=2.897, p=0.045, respectively).
GKRS is safe and effective for the management of brain metastasis from gynecologic cancers. The clinical status of the patient is important in determining the overall survival time.
妇科癌症(卵巢癌、子宫内膜癌和宫颈癌)患者发生脑转移的情况较为罕见,此前尚未评估伽玛刀放射外科治疗(GKRS)对此类疾病的疗效。我们评估了GKRS治疗妇科癌症脑转移的疗效以及肿瘤控制和生存的预后因素。
本回顾性研究经机构审查委员会批准。1995年5月至2012年10月,26例(平均年龄51.3岁,范围27 - 70岁)患有妇科癌症脑转移瘤的女性接受了GKRS治疗。我们回顾了她们的治疗结果、影像学反应和临床状况。
共有24例患者(59个病灶)可进行随访成像。中位随访时间为9个月。GKRS治疗时的平均肿瘤体积为8185立方毫米(范围10 - 19500立方毫米),肿瘤边缘的中位剂量为25 Gy(范围10 - 30 Gy)。局部肿瘤控制率为89.8%(59个肿瘤中的53个)。GKRS治疗后的中位总生存期为9.5个月(范围1 - 102个月)。年龄相关的多因素分析表明,卡诺夫斯基功能状态评分(KPS)、递归分区分析(RPA)分类以及治疗病灶数量是总生存期的重要预后因素(风险比分别为0.162,p = 0.008;0.107,p = 0.038;2.897,p = 0.045)。
GKRS治疗妇科癌症脑转移安全有效。患者的临床状况对确定总生存时间很重要。